Nearly one in three children born in the United Kingdom today are projected to develop dementia during their lifetimes, highlighting the urgency of addressing a disease that currently affects almost one million people in the country. Dementia causes approximately 75,000 deaths annually—more than cancer or heart disease—often through complications like pneumonia or difficulties swallowing. The economic impact is significant, with annual costs related to medical care and support estimated at £42 billion, a figure expected to double by 2040.

Despite the scale of the crisis, experts express concern that both the current Labour government and preceding Conservative administrations have not prioritized dementia to the extent needed. Investment disparities remain stark, with dementia research receiving roughly £1 for every £3 allocated to cancer, according to data cited by health charities.

Questions are mounting about the effectiveness of the dementia “tsar” role—the national clinical director for dementia at NHS England—established in 2010 under former Prime Minister David Cameron. Over the past 15 years, progress in dementia diagnosis and treatment has reportedly lagged far behind advances seen in cancer care, where a “cancer tsar” position has existed since 1999. Under the leadership of Professor Sir Mike Richards, who served as cancer tsar for 13 years, the NHS implemented ambitious strategies including the development of cancer networks, enhanced screening programs, and significant funding boosts. As a result, the five-year cancer survival rate in the UK has nearly doubled since the 1970s, with some cancer types seeing particularly notable improvements.

In contrast, critics argue that dementia services have made limited advances. The principal target—to increase the proportion of dementia patients receiving a diagnosis from less than one-third to two-thirds—was only recently met after a decade of effort. Some dementia experts contend that the lack of equally challenging goals has contributed to slower progress.

Interviews with healthcare professionals suggest that part of the challenge lies in limited political support rather than shortcomings from the medical experts appointed to the dementia tsar role. Professor Martin Green, chief executive of Care England, emphasizes that after an initial period of strong governmental commitment—marked by Cameron’s 2012 “Dementia Challenge”—momentum has faded. Following Cameron’s departure in 2016, the focus on dementia diminished within government, making it difficult for clinical leaders to drive change.

The current dementia tsar, Dr. Jeremy Isaacs, appointed in 2024, has publicly highlighted ongoing issues, including excessive waiting times for diagnosis. Nearly half of suspected dementia cases face delays over 18 weeks, with longer waits in socioeconomically disadvantaged areas. Timely diagnosis is critical, given the wide variety of dementia types—more than 100 in total—including Alzheimer’s disease and vascular dementia, each requiring different care approaches.

Concerns intensified earlier this year when the government announced it would remove a longstanding target requiring at least two-thirds of dementia patients in England to receive an official diagnosis. Health Secretary Wes Streeting stated this change would allow the NHS to concentrate on fewer priorities. However, advocates argue this move risks undermining progress and sending a message that dementia is a lesser priority compared to other diseases. Alzheimer’s Society has described the omission as a significant setback, warning that inconsistent diagnosis rates—some in single digits in certain regions—could hinder effective care and research.

As the UK faces a growing dementia challenge, experts call for renewed political will and ambitious strategies to emulate the earlier successes seen in cancer care, underscoring the need for a comprehensive, well-supported national plan.